Pemetrexed in Recurrent or Progressive Central Nervous System Lymphoma: A Phase I Multicenter Clinical Trial.

ABSTRACT:

Lessons learned

The findings from this study using monotherapy with pemetrexed in a pretreated patient population are, overall, encouraging. Unlike high-dose methotrexate, which requires several days of inpatient hospitalization, pemetrexed is relatively easy to administer in the outpatient setting and remains a viable treatment option in this patient population. The maximum tolerated dose of pemetrexed administered (900 mg/m² every 2 weeks) was generally well tolerated and showed activity in patients with relapsed or refractory CNSL.

Background

There is currently no standard salvage treatment for patients with relapsed/refractory central nervous system (CNS) lymphoma (CNSL). We report the results of a phase I study of pemetrexed, an antifolate drug with broader a

SUBMITTER: Dietrich J 

PROVIDER: S-EPMC7485351 | biostudies-literature | 2020 Sep

REPOSITORIES: biostudies-literature